💊 Obesity Drug Pipeline: GLP-1’s and Others MOAs for the Next Three Years…
(MOA = Mechanism of action.) Comprehensive view of the GLP‑1 and obesity-focused drug pipeline expected over the next three years (mid‑2025 to mid‑2028): 1. Dual & Triple Agonists (Injectable)Retatrutide (Eli Lilly): GLP‑1/GIP/glucagon triple agonist. Phase 2 showed ~24% weight loss at high dose over 48 weeks (Yahoo Finance, Wikipedia). Phase 3 expected in 2026–2027.CagriSema (Novo Nordisk): Semaglutide […]
🏃 Physical Activity Trajectories and Mortality: A Meta-Analysis
A systematic review and meta-analysis of 85 prospective studies, examining the long-term impact of physical activity (PA) patterns throughout adulthood on mortality. The authors aimed to understand how consistent, increasing, or decreasing PA levels are associated with all-cause, cardiovascular disease (CVD), and cancer mortality. The findings indicate that maintaining or increasing PA significantly reduces the risk of all-cause and CVD mortality, with benefits […]
Hormone Therapy Enhances Tirzepatide Weight Loss in Menopause
The source discusses research indicating that postmenopausal women on hormone therapy (HT) experience significantly greater weight loss when treated with tirzepatide, an obesity medication, compared to those not on HT. This effect mirrors prior findings with semaglutide, another weight-loss drug, suggesting a synergistic interaction where HT enhances the efficacy of these medications in this demographic. […]
⚖️ The History of Obesity
The provided text offers a comprehensive overview of how obesity has been understood and depicted across different historical periods, from ancient civilizations to the present day. It traces the evolution of obesity from being a symbol of wealth or a moral failing to its current recognition as a complex medical condition influenced by genetics, environment, and socioeconomic factors. The document highlights key shifts in medical understanding, […]
👨⚕️ AI-Driven Virtual Human for GP Obesity Training
This document presents a pilot feasibility study published in “Obesity Science & Practice” that investigates the effectiveness of an AI-driven Virtual Human (VH) intervention designed to enhance General Practitioner (GP) obesity education and communication skills. The research highlights the growing global obesity rates and the need for GPs to possess effective weight management strategies and communication abilities. The study aimed to address […]
👵 Ozempic Face: GLP-1 and Aesthetic Surgery
This scholarly article from Aesthetic Surgery Journal Open Forum discusses the phenomenon of “Ozempic Face,” a term used to describe the accelerated facial aging and volume loss experienced by some patients undergoing rapid weight loss from GLP-1 receptor agonists like Ozempic. The authors, plastic surgery residents and a practicing plastic surgeon, present a systematic review of existing literature on these medications within plastic […]
✨ GLP-1s and Post-Weight Loss Plastic Surgery Trends
There is growing evidence—especially in the plastic surgery community—that the recent surge in GLP‑1 medications (like Ozempic, Wegovy, Mounjaro) for weight loss is fueling a wave of “trim & sculpt” surgeries to address excess skin and volume loss. 📈 Trend & Clinical ReviewsThe American Society of Plastic Surgeons and multiple industry blogs report an increase […]
💉 Counterfeit Ozempic: FDA Warns of Unsafe Drug Supply (4/14/2025)
The provided text, originating from the Food and Drug Administration (FDA), serves as a crucial public health warning regarding counterfeit Ozempic (semaglutide) injections found within the U.S. drug supply chain. It details multiple instances where fake versions of the medication were identified and seized, highlighting specific lot and serial numbers to help consumers, pharmacies, and healthcare professionals identify these fraudulent products. The […]
Obesity Treatment Outcomes with Semaglutide or Tirzepatide
This original research article examines the real-world effectiveness of semaglutide and tirzepatide for obesity treatment, focusing on how medication discontinuation impacts weight loss and glycemic control. The retrospective cohort study analyzed electronic health records from a large patient population in Ohio and Florida. It reveals that discontinuation of these pharmacotherapies is common and significantly reduces the average weight reduction and improvement in glycated hemoglobin levels compared to continuous treatment. The findings suggest that maintaining […]
Orforglipron for Early Type 2 Diabetes Management
This scientific paper presents the ACHIEVE-1 trial, a phase 3 study investigating orforglipron, an oral, nonpeptide GLP-1 receptor agonist, for treating type 2 diabetes. The research evaluates its efficacy and safety as a once-daily monotherapy in adults whose type 2 diabetes is managed solely through diet and exercise. The findings demonstrate that orforglipron significantly reduces glycated hemoglobin levels and promotes body weight reduction over […]